Share Name Share Symbol Market Type Share ISIN Share Description
Abcam Plc LSE:ABC London Ordinary Share GB00B6774699 ORD 0.2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  30.00 2.23% 1,374.00 1,371.00 1,374.00 1,387.00 1,346.00 1,350.00 284,771 16:35:05
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 259.9 56.4 22.0 62.5 2,825

Abcam Share Discussion Threads

Showing 701 to 722 of 1000 messages
Chat Pages: 40  39  38  37  36  35  34  33  32  31  30  29  Older
DateSubjectAuthorDiscuss
20/5/2014
17:35
Thanks simon... I am going to start loading up my sipp at this price!
richscotsman
20/5/2014
06:56
Unicorn AIM VCT - 20/5/14 Abcam (-23%) is a global leader in the supply of innovative protein research tools. In March 2014, Abcam released its financial results for the six month period ended 31 December 2013, which were in line with your Investment Manager's internal forecasts. Revenues of £61.9m (H2 2012: £57.3m) represented half-year on half-year growth of over 8%, while earnings per share were up 6.5% to 8.74p (H2 2012: 8.21p). Abcam remains a cash generative business with a robust balance sheet. Net cash balances at the period end amounted to £35.3m. Despite Abcam's many obvious qualities, market reaction to the release of Interim Results in early March was negative as investors worried about currency headwinds and the impact of possible cuts to health budgets in the key North American market, which accounts for 43% of total sales. As a result, Abcam's share price ended the period markedly lower. The holding has been retained in the portfolio in the expectation that the de-rating in the value of Abcam will prove to be temporary.
simon gordon
06/5/2014
19:33
It's kind of bowly and sitting at the bottom of an egg, that pointy bit pointing downwards - is that the beak?
trident5
06/5/2014
19:06
Next leg up starting? Nice bowly sort of chart imo. free stock charts from uk.advfn.com
cockneyrebel
06/5/2014
19:02
Chart looks okay... Struggling against string dollar but slowly and surely we are coming back to the long term trend...
richscotsman
02/5/2014
07:10
Looking strong today.
scrabble1975
28/4/2014
19:42
I would agree, bought some myself, over last few months 4 directors at between £30K & £50K each Milners wife (Gounari) £1M+ Milner 600k of share optiions WASATCH increased holdings with 3 purchases of 2.2M, 2.4M, 2.5M shares Blackrock have reduced to less than 5% So i'm guessing that they might still be reducing holding The WASATCH site, views abc as amazon of medical world, with their on line website linking medical establishments to suppliers. They typically look for companies with growth rates of 15%+ PA. As all ways just a personal view, DYOR David
davidjljackson
27/4/2014
09:55
Did a lot of research on ABC the last couple of weeks and noting the recent heavy director buys filled my boots on Friday - seems a really good company at a reasonable price to me. Just saying.
trident5
24/4/2014
21:44
tks again !
scottishfield
24/4/2014
18:36
No worries ... Check out the longer term charts and growth trends... Also worth comparing director remuneration compared to other aim listed companies and you will see a positive growing company with good directorship!
richscotsman
24/4/2014
17:29
Scottishfield I like the ft tear sheets for financial summaries... http://markets.ft.com/research/Markets/Tearsheets/Summary?s=ABC:LSE
richscotsman
24/4/2014
15:09
what's the annual yield here guys please?
scottishfield
24/4/2014
10:26
Another £24k director buy. CR
cockneyrebel
23/4/2014
20:46
My tuppence worth... A brief blip in the chart where we have seen real value add. Those in from float or those that have done their homework will understand the growth potential in markets... Abc have invested a lot recently in research and growth and whilst the most recent results reflect a slight pull back in momentum we have the best mgmt board on aim, a growth sector within a growth market and no reason not to see an increase in share price or another take over attempt... Last one was 2007 I think... Rich
richscotsman
23/4/2014
15:05
IC analysis doesn't add anything in my view. more director buying today. not a large amount though. apad
apad
23/4/2014
15:02
£50k director buy CR
cockneyrebel
23/4/2014
15:00
ed Just means that ordinary investors are not taking much interest and the algorithms are chuntering away I suppose. apad
apad
23/4/2014
13:11
APAD, Just as a matter of interest, what significance do you attach to the fact that most trades are automatic? Is it a good or bad indicator?
edsullyjoe
23/4/2014
12:21
dont know why but I feel strangely reassured by the IC analysis!
artibee
23/4/2014
07:11
Exciting times in the Pharma Biotech sector with AZN and Pfizer , Novartis and GSK Cancer drugs are playing a MAJOR part in what is going on Today we hear of yet another new cancer drug making the news, this time for breast cancer and with a cost per treatment of £90,000 per patient. This new drug has not been approved by NICE for NHS due to the cost of it. But Cancer charities and other bodies have been/are paying for its use to date in women that have been diagnosed with HER2 +ve breast cancer , (involving a genetic mutation of a gene in the cancer cell). hTTp://www.bbc.co.uk/news/health-27113258 The drug extends the life of women with this cancer type by around nearly 6 months. Can a price be put on that ? With R&D costs going up, new drugs costing over $1 BILLION to get to market, new approved Cancer drugs are getting more expensive year on year. This one made by ROCHE has been approved in the EU and the USA. Testing the cancer tumour to ensure it is HER-2 and that it is +ve , as there is also a -ve HER2 so as to effectively treat the patient with the RIGHT drug first time is therefore a must. Doing this quickly to ensure that the drug has a chance to be as effective as possible is also a must. Globally, breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death in females. In the United States, breast cancer is the most common female cancer, the second most common cause of cancer death in women, and the main cause of death in women ages 40 to 49 years. The lifetime probability of developing invasive breast cancer is one in eight. Breast cancer is a heterogeneous, phenotypically diverse disease composed of several biologic subtypes that have distinct behavior. Amplification or overexpression of the human epidermal growth factor receptor 2 (HER2) oncogene is present in approximately 18 to 20 percent of primary invasive breast cancers HER2 type tumours are not just constrained to breast cancers, they also occur in other forms of cancer. Molecular Diagnostics testing is therefore playing an ever more important role within Cancer treatments The Source BioScience Group provide a HER2 testing service hTTp://pharma.sourcebioscience.com/our-services/stability-storage/her2.aspx
buywell2
23/4/2014
07:08
Mkt. Cap £761milliion. Move to main market? BVXP due to join AIM next week. apad
apad
22/4/2014
11:57
32 vacancies, 130,000 products, most trades automatic. apad
apad
Chat Pages: 40  39  38  37  36  35  34  33  32  31  30  29  Older
Your Recent History
LSE
ABC
Abcam
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191207 07:11:39